Dynogen Reports IBS-D Trial Results

Dynogen Pharmaceuticals has postive results from its Phase II trial of DDP225 in patients with irritable bowel syndrome with diarrhea (IBS-d).

The randomized, double-blind, placebo-controlled trial enrolled 87 women in the U.S. and Canada.

The 1-mg dose of DDP225 administered once daily for eight weeks achieved a 71 percent response rate compared with a 25 percent response rate for placebo. The drug was safe and well tolerated, Dynogen said.